Background: Although second primary cancers are a leading cause of death among men with testicular cancer, few studies have quantifi ed risks among long-term survivors. Methods: Within 14 population-based tumor registries in Europe and North America (1943-2001), we identifi ed 40 576 1-year survivors of testicular cancer and ascertained data on any new incident solid tumors among these patients. We used Poisson regression analysis to model relative risks (RRs) and excess absolute risks (EARs) of second solid cancers. All statistical tests were two-sided. Results: A total of 2285 second solid cancers were reported in the cohort. The relative risk and EAR decreased with increasing age at testicular cancer diagnosis ( P <.001); the EAR increased with attained age ( P <.001) but the excess RR decreased. Among 10-year survivors diagnosed with testicular cancer at age 35 years, the risk of developing a second solid tumor was increased (RR = 1.9, 95% confi dence interval [CI] = 1.8 to 2.1). Risk remained statistically signifi cantly elevated for 35 years (RR = 1.7, 95% CI = 1.5 to 2.0; P <.001). We observed statistically signifi cantly elevated risks, for the fi rst time, for cancers of the pleura (malignant mesothelioma; RR = 3.4, 95% CI = 1.7 to 5.9) and esophagus (RR = 1.7, 95% CI = 1.0 to 2.6). Cancers of the lung (RR = 1.5, 95% CI = 1.2 to 1.7), colon (RR = 2.0, 95% CI = 1.7 to 2.5), bladder (RR = 2.7, 95% CI = 2.2 to 3.1), pancreas (RR = 3.6, 95% CI = 2.8 to 4.6), and stomach (RR = 4.0, 95% CI = 3.2 to 4.8) accounted for almost 60% of the total excess. Overall patterns were similar for seminoma and nonseminoma patients, with lower risks observed for nonseminoma patients treated after 1975. Statistically signifi cantly increased risks of solid cancers were observed among patients treated with radiotherapy alone (RR = 2.0, 95% CI = 1.9 to 2.2), chemotherapy alone (RR = 1.8, 95% CI = 1.3 to 2.5), and both (RR = 2.9, 95% CI = 1.9 to 4.2). For patients diagnosed with seminomas or nonseminomatous tumors at age 35 years, cumulative risks of solid cancer 40 years later (i.e., to age 75 years) were 36% and 31%, respectively, compared with 23% for the general population. 
Testicular cancer is a curable malignancy, with a 10-year relative survival rate of up to 95% ( 1 , 2 ) . Because this cancer largely affects young men, a resultant lifetime exists for manifestation of the late effects of treatment, including new malignant neoplasms. Second primary cancers have emerged as a leading cause of death among testicular cancer survivors ( 3 -5 ) , although few studies have quantifi ed long-term risk. Several investigations ( 6 -9 ) describe increased risks of second cancer in testicular cancer patients with up to 10 -20 years of follow-up, but not beyond. It is thus not known whether excess risks per sist for longer periods or even whether they may eventually decrease. Moreover, estimates of the excess absolute risk of second malignant neoplasms are not available, and the effect of age at initial treatment and of attained age (age at observation) on cancer risk has not been examined. Although radiotherapy fi eld sizes and treatment doses have been reduced in recent years ( 10 , 11 ) , considerable numbers of testicular cancer patients treated in the past with more aggressive radiotherapy approaches remain at long-term risk for second cancers ( 9 ) . The heightened concern regarding the role of chemotherapy for testicular cancer in the development of solid tumors, which has been analyzed only in small series of patients with relatively short follow-up times ( 7 , 8 , 12 ) , also merits further investigation. In this study, we quantify the long-term site-specifi c absolute and relative risks of incident solid cancers among more than 40 000 1-year survivors of testicular cancer reported to population-based cancer registries in Europe and North America. A subset of patients with testicular cancer described in previous reports ( 6 , 8 , 9 , 14 ) are included, with extended follow-up.
Participating cancer registries collect data on patient demographic characteristics, tumor histology, and vital status. Three major histologic groups of testicular cancer were identifi ed: seminomatous and nonseminomatous germ cell tumors and cancers of other or unspecifi ed histologic type. Patients with extragonadal germ cell tumors or testicular lymphomas were excluded. All registries, except those in Sweden and Ontario, compile information on initial type of cancer therapy, expressed in general categories. With these data, testicular cancer patients whose primary therapy included radiotherapy and/or chemotherapy were identifi ed. Registries record data on initial, but not subsequent, courses of treatment, and details of specifi c treatment regimens, including radiotherapy fi elds, are not available in registry fi les. The known underreporting of treatment to cancer registries ( 15 ) precluded identifi cation of a defi nitive reference group of patients treated with surgery only, because this latter group may have received radiotherapy or chemotherapy as subsequent or salvage treatment.
Standard management of testicular cancer includes orchiectomy, with adjuvant regional radiotherapy or retroperitoneal lymph node dissection used for early-stage seminomas or nonseminomatous germ cell tumors, respectively ( 16 ) . When adjuvant radiotherapy was given in the past, infradiaphragmatic fi elds included para-aortic and pelvic lymph node areas, with larger doses (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) given to treat nonseminomatous germ cell tumors than to treat seminomas (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) ( 17 , 18 ) . More recently, fi elds limited to the para-aortic lymph nodes have been used to treat seminomas, and radiation doses have been reduced to 20 Gy ( 10 , 11 , 19 ) . Average doses of radiation received by several organs during simulated, standard radiotherapy techniques for testicular cancer, including chest irradiation ( 20 ) , which is no longer used, are shown in Appendix Table 1 . Since the 1970s, an increasing percentage of nonseminoma patients has been managed with retroperitoneal lymph node dissection and chemotherapy instead of radiotherapy, whereas radiotherapy has remained the standard treatment for seminoma. Since the mid1970s, patients with advanced testicular cancer have received combination chemotherapy that includes cisplatin, vinblastine, and bleomycin, with etoposide being used since the 1980s ( 23 ) . In prior years, cytotoxic therapy included cyclophosphamide, dactinomycin, mithramycin, vinblastine, and bleomycin ( 6 , 8 , 12 , 24 ) .
Invasive solid cancers diagnosed at least 1 year after testicular cancer were identifi ed through a search of cancer registry incidence fi les. Diagnoses of contralateral testicular cancer were excluded from analysis, because they were not uniformly registered by all centers. The follow-up period began 1 year after the date of testicular cancer diagnosis and ended on the date of death, date of diagnosis of a second cancer, or the study end date (December 31, 2002) 
Statistical Methods
Person-years and second cancers were categorized by histologic type of testicular cancer (seminoma, nonseminoma, or other), calendar year of testicular cancer diagnosis (1943 -1974 or 1975 -2001) , initial treatment (radiotherapy alone, chemotherapy alone, or radiotherapy and chemotherapy), and registry and by 5-year intervals of attained age, attained calendar year, time since testicular cancer diagnosis, and age at testicular cancer diagnosis. Cancer incidence rates specifi c for each registration area, male sex, and 5-year age and calendar year intervals were multiplied by the accumulated person-years at risk to estimate the number of cancer cases expected in each stratum.
In general, O and E were used to denote observed and expected numbers of incident second cancers. O ax,a,k and E ax,a,k were used to denote, respectively, observed and expected incident cases in a specifi ed category identifi ed by age at testicular cancer diagnosis ( ax ), attained age ( a ), and other variables of interest ( k ). Analyses that treated attained age, time since diagnosis, and age at diagnosis as continuous variables were based on midpoints of 5-year intervals. For example, the attained age group of 60 -64 years was assigned a value of 62.5.
Analyses were based on Poisson regression methods, in which it is assumed that the number of incident solid cancers follows a Poisson distribution with mean given by the product of the person-years and the cause-specifi c incidence rate for each cell of a multiway person-year table ( 25 -30 ) . Parameter estimates were computed with maximum likelihood methods. Hypothesis tests and confi dence intervals (CIs) were based on likelihood ratio tests and direct evaluation of the profi le likelihood. The 95% confi dence intervals shown in Appendix Table 2 were calculated as described previously by Liddell ( 31 ) . Two-sided P values are used throughout. Analyses were implemented with the AMFIT module of the software package EPICURE ( 32 ) .
Both the excess relative risk (ERR) and excess absolute risk (EAR) were evaluated. The ERR was defi ned as RR -1, where RR denotes the ratio of risk in testicular cancer patients to that in the general population. A simple unadjusted estimate of the RR is the O / E ratio. The EAR was defi ned as the difference in risks between testicular cancer patients and the general population and is expressed as the number of excess cases per 10 000 person-years. The RR is the usual measure for etiologic research and the measure that has been emphasized in most previous studies addressing second cancers. However, the EAR is a useful measure for estimating the absolute burden or magnitude of a health problem ( 33 ) . A simple unadjusted estimate of the EAR is ( O -E )/10 000 person-years. Results presented in Fig. 1 express the ERR and EAR as continuous functions of age at testicular cancer diagnosis ( ax ) and attained age ( a ) by use of the expression below:
[Eq. 1]
The parameter θ is scaled so that it represents the ERR or EAR at the attained age of 60 years for a patient diagnosed at age 35 years. The form of the model shown in Eq. 1 was selected because it has been used to model risks in other radiationexposed cohorts ( 29 , 30 ) . The fi t of this model was checked by comparing its deviance to models that estimated the ERR or EAR for categories defi ned by age at testicular cancer diagnosis and attained age.
Results were adjusted for age at testicular cancer diagnosis (see Tables 3 and 4 ) . For these analyses, the expected value of O ax,k was assumed to be
where k indexes categories defi ned by histologic type of testicular cancer, time since testicular cancer diagnosis, initial treatment, and calendar year of testicular cancer diagnosis. With this formulation, θ k represents the ERR for a patient diagnosed with testicular cancer at age 35 years, which is the average age of the cohort. For analyses of site-specifi c cancers (see Table 4 ), we fi xed the value of β to be that estimated for all solid cancers ( − 0.054) but tested whether data were compatible with this value, so that the ratios of ERRs for different cancer sites would be the same for all ages at testicular cancer diagnosis. Unless otherwise specifi ed, tables and text present relative risks for patients diagnosed at age 35 years; these data were obtained as 1 + θ k . The dependence of the ERR (and RR) on age at diagnosis is not meaningful when the ERR is negative (i.e., RR < 1). Thus, when such results occurred as lower confi dence bounds, they are reported simply as " <1. " The number of excess cancers was estimated as the sum over all cells of the terms E ax,k ERR( ax,k ). Preliminary analyses revealed statistically signifi cant heterogeneity of risk for all second solid cancers among the six countries ( P <.001), resulting from lower risks for the SEER Program and Ontario and which are likely related to migration from registry catchment areas. For this reason, the expressions in Eq. 1 were multiplied by an estimated adjustment factor, exp( λ r ), where the variable r = 1 for North American registries (SEER Program and Ontario) and latency of 10 years (see below) or more or r = 0 otherwise. The factor exp( λ ) was estimated to be about 0.7 in analyses of all solid cancers. Exploration of this adjustment indicated that, after 10 years of follow-up, this factor did not depend further on time since testicular cancer diagnosis, on age at testicular cancer diagnosis, or on attained age. After the adjustment was applied, there was no further evidence of heterogeneity among the six major registries ( P >.5).
Because there is a minimum latency interval associated with excess solid tumors related to antecedent cancer treatment and because the focus of this paper is on long-term survivors, most analyses were restricted to periods of 10 years or more after testicular cancer diagnosis. The most detailed analyses focus on all solid cancers as a single category. A combined group of in-fi eld sites (stomach, small intestine, colon, rectum, liver, gallbladder and ducts, pancreas, kidney, and bladder) that are likely to receive the highest radiation doses during infradiaphragmatic radiotherapy for testicular cancer (Appendix Table 1 ) was also evaluated. Less detailed analyses of site-specifi c cancers were also conducted.
Analyses comparing solid cancer risks for testicular cancer patients diagnosed before and after 1975 (see Table 3 ) were restricted to the 10-to 24-year period after testicular cancer diagnosis because few patients diagnosed after 1975 were followed for more than 25 years. Because data collection in the SEER Program did not begin until 1973, these patients were excluded from this set of analyses.
Cumulative probabilities of developing second solid cancers were calculated with an approach similar to that used for estimating lifetime risks from radiation exposure ( 31 ) . The approach takes into account the dependency of absolute risks on both age at testicular cancer diagnosis and attained age and dependency on competing risks from testicular cancer mortality, noncancer mortality, and any intervening diagnosis of leukemia, lymphoma, or other nonsolid cancer. The cumulative probability CUM ( ax,t ) for a person diagnosed at age ax at t years after exposure (at attained age a = ax + t ) was calculated as follows:
, where the summation is from a = ax + 1 to ax + t. SC ( a ) is the baseline risk of solid cancers and M(ax,a ) is the expression for the EAR of second cancer based on the model ( Fig. 1, B ). S(a | ax) is the probability of surviving free of a second cancer to age a, conditional on such survival to age ax . Separate calculations were made for seminoma and nonseminoma patients.
Estimating S(a | ax) required estimating risks of second cancer incidence, noncancer mortality ( NC ), testicular cancer mortality ( TC ), nonsolid cancer incidence ( NS ), and excess leukemia ( LK ) for each attained age a. S(a | ax) was then estimated as follows: 
R ESULTS
The study population consisted of 40 576 1-year survivors of testicular cancer diagnosed at an average age of 35 years (range = <1 year to 93 years). The average follow-up time was 11.3 years, with 20 984, 7885, and 2065 patients followed for 10, 20, and 30 years, respectively ( Table 1 ) . Most testicular cancers (97%) were germ cell tumors.
Second solid cancers were diagnosed in 2285 patients, but only 1619 cancers were expected ( O / E = 1.41; 95% CI = 1.35 to 1.47) (Appendix Table 2 ). Among 10-year survivors, solid cancers were diagnosed in 1694 patients ( O/E = 1.55; 95% CI = 1.48 to 1.62). Table 2 shows the number of solid tumors, the O/E ratios, and the O − E differences (per 10 000 person-years) by categories of age at testicular cancer diagnosis and attained age for 10-year survivors. Both measures decreased with increasing age at diagnosis within separate attained age categories.
To describe these patterns more effectively, the ERR and EAR for solid cancers in 10-year survivors were expressed as a function of age at testicular cancer diagnosis and attained age. A strong decrease with increasing age at testicular cancer diagnosis was observed for both the ERR and EAR ( P <.001) ( Fig. 1 ) . The EAR increased sharply with attained age ( P <.001) ( Fig. 1, B ), but the ERR decreased with attained age ( P = .004) ( Fig. 1, A ) , indicating that the increase in the EAR with attained age was less than that for the baseline risks. Parameters quantifying the effect of age at testicular cancer diagnosis and attained age were similar for seminoma and nonseminoma patients ( P >.5). For the ERR model, the parameter β in Eq. 2 was estimated as − 0.054 (95% CI = − 0.066 to − 0.042), representing a nearly threefold increase in solid cancer risk for every 20-year decrease in age at testicular cancer diagnosis.
The estimated relative risks for all solid cancers are shown in Tables 3 and 4 for men diagnosed with testicular cancer at age 35, the mean age of the cohort. Relative risks increased with increasing time since testicular cancer diagnosis ( P = .014) when evaluated over the entire follow-up period ( Table 3 ) . Relative risks in the periods of 1 -4 years and 5 -9 years were statistically signifi cantly ( P <.001) lower than those of 10 years or more since * All patients were diagnosed with testicular cancer as a fi rst primary cancer and survived 1 year or more. Of the 40 576 patients, 39 818 (98.1%) were white, 262 (0.6%) were black, and 496 (1.2%) were from other racial -ethnic groups; 2269, nine, and eight solid cancers were diagnosed in these respective groups. GCT = germ cell tumor; SEER = Surveillance, Epidemiology, and End Results.
† Mean follow-up was 11.7 years and 10.9 years for men with seminomatous and nonseminomatous GCT, respectively. Due to rounding, numbers may not sum to totals.
‡ Numbers exclude contralateral testicular cancers. § International Classifi cation of Diseases (ICD)-0 ( 35 ) morphology codes 9060 -9063. || ICD-0 ( 35 ) morphology codes 9070 -9073, 9080 -9085, and 9100 -9102. ¶ Calendar years of diagnosis of testicular cancer. # Numbers include only those patients with seminomatous or nonseminomatous GCT reported to registries that collect data on initial course of cancer treatment (SEER Program, Denmark, Finland, and Norway). Data on subsequent therapy were not available in the registry records. The initial course of treatment for patients for whom the histologic type of testicular cancer was either designated as non-GCT or was not specifi ed included radiotherapy, no chemotherapy (n = 192); chemotherapy, no radiotherapy (n = 236); radiotherapy and chemotherapy (n = 17), and other/unspecifi ed (n = 61).
diagnosis. Among 10-year survivors diagnosed at age 35 years, the relative risk was 1.9 (95% CI = 1.8 to 2.1). Risk remained statistically signifi cantly elevated for 35 years (RR = 1.7, 95% CI = 1.5 to 2.0; P <.001). During the period of 10 years or more from testicular cancer diagnosis, the relative risks declined with either attained age ( P = .004) or time since diagnosis ( P = .007) when evaluated separately; these declines persisted when analyses were restricted to patients diagnosed before 1975. Relative risks, however, remained statistically signifi cantly elevated in 35-year survivors ( P <.001). Seminoma patients had slightly higher relative risks than nonseminoma patients ( P = .088) and higher EAR, which by the attained age of 60 years was 67 per 10 000 person-years (95% CI = 57 to 77 per 10 000 person-years) for seminoma patients and 52 per 10 000 person-years (95% CI = 40 -65 per 10 000 person-years) for nonseminoma patients (difference = 15 per 10 000 person-years; 95% CI = − 0.2 to 29; P for difference = .053).
Among testicular cancer patients who survived at least 10 years, statistically signifi cantly increased risks of solid cancers were associated with radiotherapy alone (RR = 2.0, 95% CI = 1.9 to 2.2), with chemotherapy alone (RR = 1.8, 95% CI = 1.3 to 2.5), and with both (RR = 2.9, 95% CI = 1.9 to 4.2) ( Table 3 ) . Risk after radiotherapy and chemotherapy was higher than risk after radiation alone ( P = .10) or chemotherapy alone ( P = .08). For patients given radiotherapy alone, risks were 1.1 (95% CI = <1 to 1.6), 1.5 (95% CI = 1.2 to 1.9), and 2.0 (95% CI = 1.9 to 2.2), respectively, in the follow-up periods of 1 -4, 5 -9, and 10 years or more.
For seminoma patients, the relative risk of solid cancers was higher for those diagnosed 1975 and later (RR = 2.3, 95% CI = 2.0 to 2.7) than for those diagnosed before 1975 (RR = 1.9; 95% CI = 1.6 to 2.1) (difference = 0.5, 95% CI for difference = 0.05 to 0.9; P for difference = .03) ( Table 3 ) . For nonseminoma patients, however, the pattern was reversed, with a particularly striking difference when the comparison was limited to patients treated with radiation only and to sites in infradiaphragmatic radiation therapy fi elds (RR = 1.4, 95% CI = <1 to 2.9, and 4.0, 95% CI = 2.8 to 5.3, respectively; difference = − 2.6, 95% CI = < − 3 to − 0.7; P for difference = .01). With few testicular cancer patients receiving chemotherapy before 1975 (152 patients and seven solid cancers), meaningful comparisons by calendar year for other treatment groups were not possible.
We observed statistically signifi cantly elevated risks, to our knowledge for the fi rst time, for cancers of the pleura (malignant mesothelioma; RR = 3.4, 95% CI = 1.7 to 5.9) and esophagus (RR = 1.7, 95% CI = 1.0 to 2.6) ( Table 4 ) . Cancers of the lung (RR = 1.5, 95% CI = 1.2 to 1.7), colon (RR = 2.0, 95% CI = 1.7 to 2.5), bladder (RR = 2.7, 95% CI = 2.2 to 3.1), pancreas (RR = 3.6, 95% CI = 2.8 to 4.6), and stomach (RR = 4.0, 95% CI = 3.2 to 4.8) accounted for almost 60% of the total excess. The highest site-specifi c relative risks were found for cancers of the stomach, pancreas, and connective tissue, followed by cancers of the pleura and bladder, with increased risks persisting for at least 30 years for most sites. For cancers of colon, prostate, kidney, and bladder, risks remained statistically signifi cantly elevated ( P <.05) for 35 years (data not shown). Fourteen of 15 pleural cancers were histologically confi rmed as malignant mesotheliomas. Among 10-year testicular cancer survivors, there was little evidence of an increase or decrease in relative risks with additional follow-up through four decades for most sites; exceptions were statistically signifi cant negative trends for cancers of stomach ( P <.001) and lung ( P <.001) and a positive trend for kidney cancer ( P = .02). Transitional cell carcinomas of the renal pelvis (n = 20) accounted for one-third of kidney cancers for which histologic type was specifi ed (n = 61).
Among testicular cancer patients treated with radiation alone, relative risks for sites in typical infradiaphragmatic radiotherapy fi elds (RR = 2.7; 95% CI = 2.4 to 3.0) clearly exceeded those for remaining sites (RR = 1.6, 95% CI = 1.4 to 1.8). For in-fi eld sites, statistically signifi cantly increased risks persisted for 35 years or more (RR = 2.3, 95% CI = 1.8 to 3.0), with no evidence of decline ( P = .41). For remaining sites, risk appeared to decrease with time since diagnosis ( P trend = .005). Among patients given radiotherapy alone, risks were signifi cantly elevated for cancers of the stomach (RR = 4.1, 95% CI = 3.2 to 5.2), colon (RR = 1.9, 95% CI = 1.5 to 2.5), rectum (RR = 1.8, 95% CI = 1.3 to 2.5), pancreas (RR = 3.8, 95% CI = 2.7 to 5.0), lung (RR = 1.4, 95% CI = 1.1 to 1.7), pleura (RR = 4.4, 95% CI = 2.0 to 8.1), prostate (RR = 1.4, 95% CI = 1.1 to 1.8), kidney (RR = 2.8, 95% CI = 2.1 to 3.8), bladder (RR = 2.7, 95% CI = 2.1 to 3.3), malignant melanoma (RR = 1.6, 95% CI = 1.05 to 2.4), connective tissue (RR = 5.1, 95% CI = 2.4 to 9.2), and thyroid (RR = 3.1, 95% CI = 1.2 to 6.7).
There was little evidence that site-specifi c cancer risks differed by histologic type of testicular cancer or that the parameter quantifying the effect of age at testicular cancer diagnosis varied among sites. Overall, 698 (41.2%) of the 1694 solid cancers diagnosed 10 or more years after the diagnosis of testicular cancer were in excess. Cancers of stomach, colon, pancreas, lung, and bladder accounted for 397 (56.9%) of the 698 excess cases, with bladder cancer making the largest contribution (115 cases = 16.4%). Among patients initially given radiation alone, sites in typical infradiaphragmatic radiotherapy fi elds accounted for 63.7% of the excess cancers.
Cumulative risks for all solid cancers were slightly higher for seminoma patients than for nonseminoma patients ( Fig. 2 ) ; for men diagnosed with seminoma or nonseminoma at age 35 years, cumulative risks were 36% and 31%, respectively, at 40 years of ‡ Restricted to sites that are usually included in infradiaphragmatic radiotherapy fi elds for testicular cancer: stomach, small intestine, colon, rectum, liver, gallbladder and ducts, pancreas, kidney, and bladder.
follow-up compared with 23% for the general population. Cumulative risk at any given attained age increased with decreasing age at testicular cancer diagnosis. If estimated trends with age at testicular cancer diagnosis and attained age were to continue, a patient diagnosed with seminoma at age 20 years would have a cumulative risk of solid cancers of 47% by age 75 years compared with 36% and 28% for patients diagnosed at age 35 years or 50 years, respectively. * Data are restricted to those sites for which statistically signifi cantly increased relative risks were observed in 10-year survivors of testicular cancer. The RR is a decreasing function of age at testicular cancer diagnosis; results are presented for age 35 years, which is the mean age of the cohort. RR = relative risk; CI = confi dence interval; Obs. = observed number of cases.
† Percent contribution to the total excess is shown in parentheses; percentages may not sum to 100 due to rounding. ‡ P trend (negative) = .007. § Obtained as sum of site-specifi c excesses. || P trend (negative)<.001.
¶ P trend (positive) = .02. # Includes 172 tumors for which site was specifi ed and 105 tumors of unknown or ill-defi ned primary site (refer to Appendix Table 2 for complete list of solid tumors for all periods). ** P trend (negative) = .013. † † Restricted to those sites which are included in typical infradiaphragmatic radiotherapy fi elds for testicular cancer: stomach, small intestine, colon, rectum, liver, gallbladder and ducts, pancreas, kidney, and bladder.
‡ ‡ P trend (negative) = .005.
D ISCUSSION
This is, to our knowledge, the largest study to date of testicular cancer patients; it includes more than 7800 20-year and 2065 30-year survivors in a population-based setting. By analyzing more than 2200 solid cancers, we were able to evaluate risk in relation to time since diagnosis of testicular cancer (over four decades), age at testicular cancer diagnosis, attained age, testicular cancer histology, type of initial therapy, and calendar year. New fi ndings include the strong age dependence of excess cancers, the persistence of statistically signifi cantly increased risks of cancer for at least 35 years after testicular cancer diagnosis, and statistically signifi cant associations between the receipt of chemotherapy and the risk of a second cancer. We also identifi ed, to our knowledge for the fi rst time, statistically signifi cant excesses of cancers of the pleura and esophagus. The overall constellation of increased site-specifi c risks of solid tumors was similar for seminoma and nonseminoma patients. Nonseminoma patients treated in more recent decades (1975 -2001) had lower risks of solid tumors than those treated in earlier periods.
In contrast to most cohort studies of testicular cancer survivors ( 7 -9 , 12 , 14 , 36 -38 ) , multivariable modeling was used to evaluate solid tumor risks. Adjustment for age at testicular cancer diagnosis was especially important, because this factor was related both to solid cancer risk and to other variables such as tumor histology and time since diagnosis. A particularly striking fi nding was the strong increase in both the ERR and EAR of solid tumors with decreasing age at testicular cancer diagnosis. A patient treated for seminoma or nonseminoma at age 20 years, for example, had an ERR of solid cancers that was about three times higher than that of a patient treated at age 40 years. The ERR declined with attained age, indicating that the EAR did not increase as rapidly as background rates. Nevertheless, the EAR showed a strong increase with attained age over the 40-year follow-up period included in our study. Although it is not known whether risks continue to increase beyond 40 years, the fi nding could have important implications regarding future cancer risks, especially for young testicular cancer patients. For example, a patient diagnosed with seminoma at age 20 years would be projected to have a cumulative risk of solid cancers of almost 50% by age 75 years.
Several studies of testicular cancer patients, but not all ( 39 ) , have identifi ed statistically signifi cantly increased risks for cancers of gastrointestinal and genitourinary tracts and other sites. A comprehensive discussion of site-specifi c risks was included in a prior survey ( 9 ) ; in this study, we supplement this number with an additional 11 733 testicular cancer patients and 1034 new solid cancers. We focus below on long-term cancer risk for selected sites included in typical radiotherapy fi elds for testicular cancer, with consideration given to organ doses received during these treatments (Appendix Table 1 ).
Infradiaphragmatic Cancers (Bladder, Stomach, Pancreas, or Kidney)
Among 10-year survivors of testicular cancer initially given radiotherapy, the relative risks of solid tumors at sites included in typical infradiaphragmatic fi elds were considerably higher than those at sites not in the fi eld ( Table 4 ). In particular, elevated risks of bladder cancer were described previously ( 8 , 9 ) , with extended follow-up now showing no evidence for a diminution in risk, even 35 years or more after treatment. During iliac radiotherapy for testicular cancer, ipsilateral portions of bladder are exposed to full-dose irradiation, whereas remaining sites receive scattered dose. Given the statistically signifi cant dose -response relation evident for radiation and bladder cancer ( 40 ) , reductions in fi eld size and radiotherapy doses for testicular cancer ( 10 , 11 ) may translate into decreased risks in the future.
Excess stomach cancers after treatment for testicular cancer ( 7 , 9 , 41 ) are consistent with the large doses of radiation received by this organ during abdominal radiotherapy. Although increased risks of stomach cancer persisted for at least 30 years, the magnitude of excess relative risk decreased statistically signifi cantly with extended observation time. The stomach was the only infradiaphragmatic organ for which such a temporal pattern was evident, with additional follow-up needed to confi rm this fi nding.
Sparse data indicate that pancreatic cancer may follow therapeutic amounts of radiation ( 42 , 43 ) , with little evidence for induction at lower doses ( 44 , 45 ) . Radiotherapy for testicular cancer can result in pancreas doses of up to 28 Gy. Statistically significant excesses of pancreas cancer, which have been observed in several surveys of testicular cancer patients ( 6 -9 , 46 ) but not others ( 7 , 8 , 37 , 38 ) , are now confi rmed, with excesses persistent for more than three decades.
Excess relative risks of kidney cancer continued to increase 10 years or more after testicular cancer diagnosis. During para-aortic radiotherapy for testicular cancer, medial sections of kidney parenchyma and renal pelvis receive radiation doses up to 10 Gy, which may account for the sizable proportion of transitional cell carcinomas of the renal pelvis that we observed. Although kidney cancer is not universally regarded as radiogenic ( 45 ) , radiotherapy for cervical cancer (average kidney dose = 2 Gy) resulted in statistically signifi cantly increased risks for 30 years or more ( 47 ) . It is not clear whether cytotoxic and/or radiosensitizing drugs might contribute to excess kidney cancers in long-term testicular cancer survivors ( 48 -50 ) .
Supradiaphragmatic Cancers (Esophagus, Pleura, or Lung)
To our knowledge, this is the fi rst report of statistically signifi cantly increased risks of cancers of esophagus and pleura among testicular cancer patients. Our results should be considered in relation to the supradiaphragmatic radiotherapy fi elds frequently applied in the past ( 5 , 20 , 51 ) , which delivered an average dose of 21.5 Gy or more to the esophagus. Excess esophageal cancers have been reported after therapeutic chest irradiation for breast cancer ( 52 ) and Hodgkin lymphoma ( 53 ) . Previous case reports ( 54 ) record the occurrence of pleural mesothelioma after chest radiotherapy for Hodgkin lymphoma, breast cancer, and testicular cancer (one patient). Neugut et al. ( 55 ) , in an analysis of SEER Program data, found a slight, non -statistically signifi cant risk of mesothelioma after radiotherapy, based on only two cases among women with breast cancer. Our series, with 14 mesotheliomas, is the largest yet reported. Among men initially treated with radiotherapy alone, the risk of pleural cancer was increased (RR = 4.0, 95% CI = 2.0 to 8.1), thus adding to the mounting evidence that very high doses of radiation might be causally related to cancers at this site.
Lung cancer accounted for the fourth-largest number of excess solid tumors. Hoff Wanderas et al. ( 8 ) , whose patients are included in this series with updated follow-up, reported a statistically signifi cantly increased twofold to fi vefold risk of lung cancer (28 cases) after testicular cancer, most often after chest irradiation. Similarly, van Leeuwen et al. ( 7 ) observed nonstatistically signifi cant 2.5-fold lung cancer excesses (four cases) among a subgroup of 141 testicular cancer patients given mediastinal radiotherapy. During such chest radiation, medial portions of lung received up to 16.8 Gy. By extrapolating from our fi ndings in a previous case -control study ( 48 ) , it can be estimated that about 16% of testicular cancer patients in this series may have received chest radiotherapy. Statistically signifi cant dose-dependent risks of lung cancer have been observed among patients given thoracic radiotherapy for Hodgkin lymphoma ( 56 -58 ) and breast cancer ( 59 ) . Whether tobacco use might contribute to the lung cancer fi ndings is unknown, but there is no reason to believe that the prevalence of smoking in testicular cancer patients exceeds that in the general population ( 60 ) .
Other Findings
The decrease in the risk of solid tumors for nonseminoma patients treated since 1975 compared with those treated in prior calendar years likely refl ects several factors, including the introduction of effective chemotherapy; the decreased use of radiotherapy, with lower doses and smaller fi elds; and the application of surveillance policies ( 61 , 62 ) . Extended followup, however, is needed to determine whether lowered risks will continue throughout the third and fourth decades after treatment. The continued use of radiotherapy after 1975 in most seminoma patients ( 63 ) may be the reason why similar decreases in risk were not observed in this group; there is no obvious explana tion for the apparent increase in risk, and this may represent a chance fi nding, given the large number of comparisons that were made.
Platinum-based chemotherapy for testicular cancer has been linked with statistically signifi cant dose-dependent increased risks of leukemia ( 48 ) , and sparse data have suggested associations with solid cancers ( 7 , 8 , 12 ) . We document that treatment of testicular cancer with chemotherapy alone is associated with statistically signifi cantly increased risks of solid cancers, but analytic studies will be required to quantify treatment-specifi c risks and determine their causes. Platinum is retained in the human body long after the completion of treatment ( 64 -66 ) and causes solid tumors in preclinical studies ( 50 ) .
From small numbers and former treatment schedules, it has been suggested that chemotherapy for testicular cancer enhances the risk of radiotherapy-associated solid tumors ( 8 , 36 ) . Testicular cancer patients treated with chemotherapy and radiotherapy in the current series experienced a larger risk of solid tumors than those given radiotherapy alone, but the difference was not statistically signifi cant. Few patients (n = 782), however, received combined modality therapy.
Comment
Our results should be viewed within the context of the strengths and limitations of cancer registry -based data. Population-based studies minimize the selection bias inherent in hospital or clinical series and allow evaluation of site-specifi c second cancer risk among many patients. Underreporting of second cancers among patients who emigrate from registry catchment areas is unlikely in Nordic countries, which have nationwide registration, but it is a concern in more localized North American registries, and we adjusted the analysis for this possible shortcoming.
Another limitation of this study is that treatment designation represents only initial management, without consideration of salvage treatment. Thus, misclassifi cation may serve to dampen any differences between therapeutic categories. Further, radiation doses to specifi c organs of individual patients were not computed, and inferences were made on the basis of typical treatments. Details of the chemotherapy regimens also were not known. In any analysis of multiple primary cancers, the sizable number of comparisons may produce some statistically signifi cant associations by chance alone.
Although the discussion above focuses on treatment as the primary explanation for the observed excesses, it should be kept in mind that elevated patterns of solid tumor risk may also refl ect the infl uence of natural history, diagnostic surveillance, and shared etiologic factors ( 67 ) . Several reports ( 12 , 36 , 68 ) conclude that testicular cancer patients do not appear at inherently elevated risk of solid tumors. One promising testicular cancer susceptibility gene has been mapped to chromosome Xq27 ( 69 ) . Identifi cation and characterization of such a gene(s) may facilitate elucidation of any contribution of shared genetic susceptibility to excess tumors in testicular cancer patients. Treatment can probably explain much of the observed excess in this study, an interpretation that is supported by the lower risks in the fi rst 10 years of follow-up, when radiation-related cancers would be infrequent, and by the especially high risks for cancer sites in standard radiotherapy fi elds.
Nevertheless, our results provide a reasonable gauge of the risk of solid tumors among long-term testicular cancer survivors and serve to heighten clinician and patient awareness of this risk. Testicular cancer survivors should be encouraged to adopt practices that are consistent with a healthy lifestyle, including smoking cessation ( 70 ) ; to seek medical consultation for any persistent changes in health status; and to follow screening guidelines applicable to the general population ( 71 ) . In future investigations, radiation doses to second cancer sites should be quantifi ed with the cumulative doses of specifi c cytotoxic drugs to clarify the contribution of treatment effects. Future evaluations should also assess interactions of therapy with other genetic and environmental determinants of sitespecifi c cancer risk ( 67 ) .
Despite the statistically signifi cantly increased long-term risk of second solid tumors, it is clear that the remarkable gains in survival provided by treatments for testicular cancer far outweigh the risk of this serious late effect, and generalization of our results to modern practice should be undertaken with caution. Given current modifi cations in treatment that result in lower radiation doses ( 10 , 11 , 72 , 73 ) , solid tumors in the future will probably have considerably less impact on the lives of testicular cancer survivors, although careful follow-up is necessary to reliably quantify long-term risk. * Radiation doses to target organs were estimated with methods as described by Stovall et al. ( 21 ) . Treatment simulation was based on standard anterior -posterior (AP)/posterior -anterior para-aortic and iliac fi elds (total administered doses of 50 Gy and 30 Gy) or para-aortic fi elds only (20 Gy) ( 22 ) . Mediastinal radiotherapy included the left supraclavicular fossa ( 20 ) . Although representative fi elds during the study period are shown above, radiation doses for individual patients are not available but likely fall within the range of values presented. Gy = gray.
† Average doses to the upper and middle third of the esophagus are 8.4 and 28.3 Gy, respectively. ‡ The range represents doses to different segments of the colon (ascending, transverse, descending, and sigmoid). § Average doses to the medial and lateral parts of the lung are 16.8 and 1.2 Gy, respectively. || For para-aortic and iliac fi elds, doses are listed for the unblocked kidney. Doses to the blocked kidney are 6.0 Gy and 3.6 Gy for treatment doses of 50 Gy and 30 Gy, respectively.
¶ Average doses to the left and right lobes of the thyroid are 25.2 and 5.7 Gy, respectively. * Unadjusted observed-to-expected (O/E) ratios were calculated by use of a standard approach ( 9 ) . Site-specifi c O/E ratios did not differ statistically signifi cantly between seminoma patients and patients with nonseminomatous germ cell tumors. CI = confi dence interval.
Appendix
† Observed minus expected. ‡ Numbers exclude contralateral testicular cancers. Of the 2285 testicular cancer patients who developed a second solid tumor, 192 subsequently developed a third or higherorder invasive cancer (n = 242 cases).
§ Fourteen of 15 pleural cancers were histologically confi rmed as malignant mesothelioma. For one patient, histology was not specifi ed. || Histologic subtype was specifi ed for 82 cancers (59 renal cell carcinoma and 23 transitional cell carcinoma). ¶ Includes all solid tumors not itemized in table (i.e., those of unknown or ill-defi ned primary site).
